ORYZF (Oryzon Genomics) Other Operating Expense: $14.51 Mil (TTM As of Mar. 2026)


ORYZF Oryzon Genomics SA ORYZF
31 GF Score
Price $3.66
View Full Analysis

What is Oryzon Genomics Other Operating Expense?

Oryzon Genomics ORYZF 31 Other Operating Expense is $14.51 Mil as of Mar. 2026. GuruFocus rates ORYZF with a GF Score™ of 31/100.

Oryzon Genomics's Other Operating Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $14.51 Mil.

Oryzon Genomics's quarterly Other Operating Expense increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($10.99 Mil) but then declined from Dec. 2025 ($10.99 Mil) to Mar. 2026 ($0.00 Mil).

Oryzon Genomics's annual Other Operating Expense declined from Dec. 2023 ($20.45 Mil) to Dec. 2024 ($11.95 Mil) but then increased from Dec. 2024 ($11.95 Mil) to Dec. 2025 ($19.22 Mil).

Oryzon Genomics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Other Operating Expense Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.11 22.22 20.45 11.95 19.22

Oryzon Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.52 0.00 10.99 0.00
ORYZF
31GF Score
Oryzon Genomics SA ORYZF
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $14.51 Mil mean?
Oryzon Genomics (ORYZF) has a Other Operating Expense of $14.51 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Oryzon Genomics and its competitors.
Is Oryzon Genomics' Other Operating Expense too high?
Oryzon Genomics' current Other Operating Expense is $14.51 Mil. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Other Operating Expense compare to VRTX and REGN?
Oryzon Genomics' Other Operating Expense of $14.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Oryzon Genomics and its competitors. Oryzon Genomics's current Other Operating Expense is $14.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current Other Operating Expense of $14.51 Mil. The current Other Operating Expense is $14.51 Mil. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current Other Operating Expense is $14.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Other Exchanges 0RDB:UKORY:SpainORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for ORYZF

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.66
Price